KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Neogenomics (NEO) over the last 17 years, with Q4 2025 value amounting to 7.05%.

  • Neogenomics' EBITDA Margin rose 36400.0% to 7.05% in Q4 2025 from the same period last year, while for Dec 2025 it was 15.93%, marking a year-over-year decrease of 19900.0%. This contributed to the annual value of 15.93% for FY2025, which is 19900.0% down from last year.
  • Latest data reveals that Neogenomics reported EBITDA Margin of 7.05% as of Q4 2025, which was up 36400.0% from 14.38% recorded in Q3 2025.
  • In the past 5 years, Neogenomics' EBITDA Margin registered a high of 7.05% during Q4 2025, and its lowest value of 44.4% during Q1 2022.
  • In the last 5 years, Neogenomics' EBITDA Margin had a median value of 18.7% in 2021 and averaged 20.87%.
  • Per our database at Business Quant, Neogenomics' EBITDA Margin crashed by -374600bps in 2021 and then soared by 188400bps in 2023.
  • Neogenomics' EBITDA Margin (Quarter) stood at 33.06% in 2021, then soared by 42bps to 19.02% in 2022, then skyrocketed by 37bps to 11.94% in 2023, then grew by 10bps to 10.7% in 2024, then soared by 34bps to 7.05% in 2025.
  • Its last three reported values are 7.05% in Q4 2025, 14.38% for Q3 2025, and 26.27% during Q2 2025.